WallStSmart

Cross Country Healthcare Inc (CCRN)vsJohnson & Johnson (JNJ)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 9674% more annual revenue ($97.93B vs $1.00B). JNJ leads profitability with a 21.5% profit margin vs -9.8%. JNJ appears more attractively valued with a PEG of 4.14. JNJ earns a higher WallStSmart Score of 57/100 (C).

CCRN

Hold

36

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.7Quality: 9.0
Piotroski: 4/9Altman Z: 4.25

JNJ

Buy

57

out of 100

Grade: C

Growth: 4.7Profit: 8.5Value: 4.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCRNUndervalued (+37.2%)

Margin of Safety

+37.2%

Fair Value

$13.17

Current Price

$13.25

$0.08 discount

UndervaluedFair: $13.17Overvalued

Intrinsic value data unavailable for JNJ.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCRN3 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.2510/10

Safe zone — low bankruptcy risk

JNJ5 strengths · Avg: 8.8/10
Market CapQuality
$615.36B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
24.8%9/10

Every $100 of equity generates 25 in profit

Profit MarginProfitability
21.5%9/10

Keeps 22 of every $100 in revenue as profit

Operating MarginProfitability
28.6%8/10

Strong operational efficiency at 28.6%

Free Cash FlowQuality
$3.39B8/10

Generating 3.4B in free cash flow

Areas to Watch

CCRN4 concerns · Avg: 2.3/10
Market CapQuality
$428.06M3/10

Smaller company, higher risk/reward

PEG RatioValuation
12.622/10

Expensive relative to growth rate

Return on EquityProfitability
-31.5%2/10

ROE of -31.5% — below average capital efficiency

Revenue GrowthGrowth
-17.8%2/10

Revenue declined 17.8%

JNJ3 concerns · Avg: 2.7/10
P/E RatioValuation
29.1x4/10

Moderate valuation

PEG RatioValuation
4.142/10

Expensive relative to growth rate

EPS GrowthGrowth
-1.0%2/10

Earnings declined 1.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : CCRN

The strongest argument for CCRN centers on Price/Book, Debt/Equity, Altman Z-Score.

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 28.6%.

Bear Case : CCRN

The primary concerns for CCRN are Market Cap, PEG Ratio, Return on Equity.

Bear Case : JNJ

The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

CCRN profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.

CCRN carries more volatility with a beta of 0.45 — expect wider price swings.

JNJ is growing revenue faster at 6.6% — sustainability is the question.

JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.

Bottom Line

JNJ scores higher overall (57/100 vs 36/100), backed by strong 21.5% margins. CCRN offers better value entry with a 37.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cross Country Healthcare Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Cross Country Healthcare, Inc. provides talent management and other consulting services for healthcare clients in the United States. The company is headquartered in Boca Raton, Florida.

Visit Website →

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Want to dig deeper into these stocks?